trending Market Intelligence /marketintelligence/en/news-insights/trending/-nqXyc9a0Hafj0tgBgTxWg2 content esgSubNav
In This List

Collegium terminates opioid drug license agreement with BioDelivery

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Collegium terminates opioid drug license agreement with BioDelivery

Collegium Pharmaceutical Inc. is returning to BioDelivery Sciences International Inc. the U.S. rights to opioid drug Onsolis.

The companies entered a license and development agreement for the drug in May 2016, and have since been collaborating on the transfer of product manufacturing to a new supplier.

Collegium's decision to terminate the license involves its recent license agreement to commercialize Depomed Inc.'s Nucynta.

The termination will be effective March 8, 2018.